Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ761242B2 - Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF - Google Patents
[go: Go Back, main page]

NZ761242B2 - Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF - Google Patents

Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF Download PDF

Info

Publication number
NZ761242B2
NZ761242B2 NZ761242A NZ76124216A NZ761242B2 NZ 761242 B2 NZ761242 B2 NZ 761242B2 NZ 761242 A NZ761242 A NZ 761242A NZ 76124216 A NZ76124216 A NZ 76124216A NZ 761242 B2 NZ761242 B2 NZ 761242B2
Authority
NZ
New Zealand
Prior art keywords
vegf
patient
vegf inhibitor
macular degeneration
genetic
Prior art date
Application number
NZ761242A
Other versions
NZ761242A (en
Inventor
Sara Hamon
Charles Paulding
Lorah Perlee
Original Assignee
Regeneron Pharmaceuticals Inc
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority claimed from NZ744025A external-priority patent/NZ744025A/en
Publication of NZ761242A publication Critical patent/NZ761242A/en
Publication of NZ761242B2 publication Critical patent/NZ761242B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Disclosed herein are methods for associating a genetic variant with improved visual acuity in patients with wet macular degeneration who have previously been treated with a VEGF inhibitor for about one year, wherein the genetic variant is rs2106124 or rs1879796. Also disclosed is the treatment of these patients with a VEGF inhibitor in an amount of about 2mg quarterly.

Claims (11)

What is claimed is:
1. Use of a vascular endothelial growth factor (VEGF) inhibitor in the manufacture of a medicament for the treatment of a wet macular degeneration patient, the patient having previously been treated with the VEGF inhibitor for about one year, the patient having one or more genetic variants determined by performing or having performed a genotype assay on a DNA sample obtained from the t, wherein the one or more genetic variants are single nucleotide rphisms rs2106124 or rs1879796, and wherein the VEGF inhibitor is formulated for intravitreal administration to the patient in an amount of about 2 mg quarterly after the about one year previous treatment with the VEGF tor.
2. The use of claim 1, wherein the single nucleotide polymorphism is rs2106124.
3. The use of claim 1, wherein the single nucleotide polymorphism is rs1879796.
4. The use of any one of claims 1 to 3, wherein the VEGF inhibitor is ranibizumab.
5. The use of any one of claims 1 to 3, wherein the VEGF inhibitor is aflibercept.
6. A method of associating a c variant with improved visual acuity in a wet macular degeneration patient having usly been treated with a VEGF inhibitor for about one year, the method comprising: performing a genotype assay on a DNA sample obtained from the patient to determine the presence or absence of the genetic variant ated with improved visual , n the genetic variant is rs2106124 or rs1879796, wherein when the patient has the genetic variant, the patient is a candidate for intravitreal administration with a VEGF tor in an amount of about 2 mg quarterly.
7. The method of claim 6, wherein the genetic variant is rs2106124.
8. The method of claim 6, wherein the genetic t is rs1879796.
9. The method of any one of claims 6 to 8, wherein the VEGF inhibitor is ranibizumab.
10. The method of any one of claims 6 to 8, wherein the VEGF inhibitor is aflibercept.
11. The method of any one of claims 6 to 10, wherein the improved visual acuity is a Gain of 15 letters. ”Hi/8 gm gmmgmnmanm m ?wmamé 3m ??w 3% ”mam”. 3mm a“ msmwamn? émmwm gamma: .xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
NZ761242A 2016-12-01 Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF NZ761242B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262589P 2015-12-03 2015-12-03
US201662291274P 2016-02-04 2016-02-04
NZ744025A NZ744025A (en) 2015-12-03 2016-12-01 Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf

Publications (2)

Publication Number Publication Date
NZ761242A NZ761242A (en) 2024-10-25
NZ761242B2 true NZ761242B2 (en) 2025-01-28

Family

ID=

Similar Documents

Publication Publication Date Title
IL259672B2 (en) Methods for associating genetic variants with clinical outcome in patients suffering from age-related macular degeneration and receiving treatment against tubular endothelial growth factor
Finger et al. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
Abu-Amero et al. Screening of the seed region of MIR184 in keratoconus patients from Saudi Arabia
WO2009059318A3 (en) Genes and polymorphisms associated with amd
Saify et al. Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence
WO2006096737A3 (en) Diagnostic and therapeutic target for macular degeneration
EA201290107A1 (en) METHOD FOR DETERMINING A PATIENT AS A SUSTAINABLE OR NOT SUSTAINABLE FOR IMMUNOTHERAPY
Le et al. Functional annotation of genetic loci associated with sepsis prioritizes immune and endothelial cell pathways
Tomkowiak et al. Identification of leaf rust resistance genes Lr34 and Lr46 in common wheat (Triticum aestivum L. ssp. aestivum) lines of different origin using multiplex PCR
Khanaliha et al. Double-stranded RNA viral infection of Trichomonas vaginalis (TVV1) in Iranian isolates
NZ761242B2 (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
NZ761246B2 (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
EP3762035A1 (en) Compositions and methods for the diagnosis and treatment of alt cancer
Thakur et al. Genetic diversity in the C-terminal 42 kDa region of merozoite surface protein-1 of Plasmodium vivax (PvMSP-142) among Indian isolates
CN104120170B (en) Potato early blight bacterium detection kit and detection method
JP2016214086A (en) Mutation detection method and kit of egfr gene
CN104726608B (en) Application method of VEGFR2 gene Val297Ile site
RU2014110271A (en) SUSCEPTIBILITY TO ANGIOGENESIS INHIBITORS
EA201992112A1 (en) TREATMENT TREATMENT METHODS
Moron et al. Detection of azole resistance and ERG11 point mutations in Candida albicans isolates from tertiary hospitals in the Philippines
MX2019007012A (en) Human genetic markers associated with response to treatments that target clostridium difficile toxin b.
ES2535577A2 (en) METHOD FOR THE DIAGNOSIS OF VERTICILOSIS IN THE OLIVE TREE
Dosunmu-Ogunbi et al. The role of SOD2 in maintaining endothelial cell function in SCD
Hobbs et al. B37 TELL ME WHY: COPD PATHOGENESIS: Coding Variant Associations With Lung Function And COPD Using An Exome Array
CN116855602A (en) Kit for detecting resistance of intraocular anti-VEGF therapeutic drug